Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Acute pancreatitis promotes the generation of two different exosome populations

  • Jiménez-Alesanco, A.
  • Marcuello, M.
  • Pastor-Jiménez, M.
  • López-Puerto, L.
  • Bonjoch, Laia|||0000-0002-3351-0037
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Carrascal Pérez, Montserrat|||0000-0002-0205-2176
  • Abian, Joaquin|||0000-0003-2823-5429
  • de-Madaria, Enrique|||0000-0002-2412-9541
  • Closa Autet, Daniel|||0000-0003-3797-3095
Exosomes are small extracellular vesicles that act as intercellular messengers. Previous studies revealed that, during acute pancreatitis, circulating exosomes could reach the alveolar compartment and activate macrophages. However, proteomic analysis suggested that the most likely origin of these exosomes could be the liver instead of the pancreas. The present study aimed to characterize the exosomes released by pancreas to pancreatitis-associated ascitic fluid (PAAF) as well as those circulating in plasma in an experimental model of taurocholate-induced acute pancreatitis in rats. We provide evidence that during acute pancreatitis two different populations of exosomes are generated with relevant differences in cell distribution, protein and microRNA content as well as different implications in their physiological effects. During pancreatitis plasma exosomes, but not PAAF exosomes, are enriched in the inflammatory miR-155 and show low levels of miR-21 and miR-122. Mass spectrometry-based proteomic analysis showed that PAAF exosomes contains 10-30 fold higher loading of histones and ribosomal proteins compared to plasma exosomes. Finally, plasma exosomes have higher pro-inflammatory activity on macrophages than PAAF exosomes. These results confirm the generation of two different populations of exosomes during acute pancreatitis. Deep understanding of their specific functions will be necessary to use them as therapeutic targets at different stages of the disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Urinary Proteome Analysis Identified Neprilysin and VCAM as Proteins Involved in Diabetic Nephropathy

  • Guillén Gómez, Elena|||0000-0002-8498-2579
  • Bardají de Quixano, Beatriz|||0000-0001-7456-355X
  • Ferrer, Sílvia
  • Brotons, Carlos|||0000-0001-9388-6581
  • Knepper, Mark A.
  • Carrascal Pérez, Montserrat|||0000-0002-0205-2176
  • Abian, Joaquin|||0000-0003-2823-5429
  • Mas, José M.
  • Calero, Francesca|||0000-0002-5758-0769
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Fernandez-Llama, Patricia|||0000-0002-7472-2124
Urinary proteome was analyzed and quantified by tandem mass tag (TMT) labeling followed by bioinformatics analysis to study diabetic nephropathy (DN) pathophysiology and to identify biomarkers of a clinical outcome. We included type 2 diabetic normotensive non-obese males with (n = 9) and without (n = 11) incipient DN (microalbuminuria). Sample collection included blood and urine at baseline (control and DN basal) and, in DN patients, after 3 months of losartan treatment (DN treated). Urinary proteome analysis identified 166 differentially abundant proteins between controls and DN patients, 27 comparing DN-treated and DN-basal patients, and 182 between DN-treated patients and controls. The mathematical modeling analysis predicted 80 key proteins involved in DN pathophysiology and 15 in losartan effect, a total of 95 proteins. Out of these 95, 7 are involved in both processes. VCAM-1 and neprilysin stand out of these 7 for being differentially expressed in the urinary proteome. We observed an increase of VCAM-1 urine levels in DN-basal patients compared to diabetic controls and an increase of urinary neprilysin in DN-treated patients with persistent albuminuria; the latter was confirmed by ELISA. Our results point to neprilysin and VCAM-1 as potential candidates in DN pathology and treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Evidence in chronic kidney disease-mineral and bone disorder guidelines, Is it time to treat or time to wait?

  • Bover, Jordi|||0000-0003-3577-2273
  • Ureña-Torres, Pablo|||0000-0001-6757-1906
  • Mateu, Silvia
  • DaSilva Santos, Iara|||0000-0001-8203-6135
  • Gràcia, Silvia
  • Sánchez-Baya, Maya|||0000-0003-1689-9383
  • Arana Aliaga, Carolt|||0000-0003-1100-5758
  • Fayos de Arizón, Leonor|||0000-0002-9277-645X
  • Guirado, Luis|||0000-0001-5119-3912
  • Cozzolino, Mario|||0000-0002-8494-6252
Chronic kidney disease-mineral and bone disorder (CKD-MBD) is one of the many important complications associated with CKD and may at least partially explain the extremely high morbidity and mortality among CKD patients. The 2009 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline document was based on the best information available at that time and was designed not only to provide information but also to assist in decision-making. In addition to the international KDIGO Work Group, which included worldwide experts, an independent Evidence Review Team was assembled to ensure rigorous review and grading of the existing evidence. Based on the evidence from new clinical trials, an updated Clinical Practice Guideline was published in 2017. In this review, we focus on the conceptual and practical evolution of clinical guidelines (from eMinence-based medicine to eVidence-based medicine and 'living' guidelines), highlight some of the current important CKD-MBD-related changes, and underline the poor or extremely poor level of evidence present in those guidelines (as well as in other areas of nephrology). Finally, we emphasize the importance of individualization of treatments and shared decision-making (based on important ethical considerations and the 'best available evidence'), which may prove useful in the face of the uncertainty over the decision whether 'to treat' or 'to wait'.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Early Macrophage Infiltration and Sustained Inflammation in Kidneys From Deceased Donors Are Associated With Long-Term Renal Function

  • Guillén-Gómez, E.
  • Dasilva, I.
  • Silva, Irene|||0000-0002-2723-1031
  • Arce, Yolanda
  • Facundo, Carme|||0000-0003-1254-5553
  • Ars, Elisabet|||0000-0002-4118-4358
  • Breda, Alberto|||0000-0002-7842-9048
  • Ortiz, Alberto|||0000-0002-9805-9523
  • Guirado, Luis|||0000-0001-5119-3912
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
Kidney transplants from living donors (LDs) have a better outcome than those from deceased donors (DDs). Different factors have been suggested to justify the different outcome. In this study, we analyzed the infiltration and phenotype of monocytes/macrophages and the expression of inflammatory and fibrotic markers in renal biopsy specimens from 94 kidney recipients (60 DDs and 34 LDs) at baseline and 4 months after transplantation. We evaluated their association with medium- and long-term renal function. At baseline, inflammatory gene expression was higher in DDs than in LDs. These results were confirmed by the high number of CD68-positive cells in DD kidneys, which correlated negatively with long-term renal function. Expression of the fibrotic markers vimentin, fibronectin, and α-smooth muscle actin was more elevated in biopsy specimens from DDs at 4 months than in those from LDs. Gene expression of inflammatory and fibrotic markers at 4 months and difference between 4 months and baseline correlated negatively with medium- and long-term renal function in DDs. Multivariate analysis point to transforming growth factor-β1 as the best predictor of long-term renal function in DDs. We conclude that early macrophage infiltration, sustained inflammation, and transforming growth factor-β1 expression, at least for the first 4 months, contribute significantly to the difference in DD and LD transplant outcome.